Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Haferkamp

Showing results (161-170 of 298) with videos related to

Pageof 30
Sort By:
Translational Oncology|June 10, 2015
Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line TherapeuticsStefan Vallo, Martin Michaelis, Florian Rothweiler, et al.
Urologic Oncology|August 5, 2019
Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancerRene Mager, Olga Savko, Katharina Böhm, et al.
World Journal of Urology|November 1, 2022
Negative multiparametric magnetic resonance imaging for prostate cancer: further outcome and consequencesMaximilian Haack, Vanessa Miksch, Zhe Tian, et al.
World Journal of Urology|June 30, 2025
Impact of the PI-QUAL MRI quality score on histopathological up-staging from MRI fusion biopsy to final prostatectomy specimenMaximilian Haack, Mohamad Turkman, Tobias Jorg, et al.
Cancer Medicine|June 26, 2024
Challenges and perspectives in use of artificial intelligence to support treatment recommendations in clinical oncologyGregor Duwe, Dominique Mercier, Crispin Wiesmann, et al.
Oncology Letters|November 9, 2017
Blocking integrin β1 decreases adhesion in chemoresistant urothelial cancer cell linesStefan Vallo, Jochen Rutz, Miriam Kautsch, et al.
Oncology Reports|December 29, 2015
Autophagy-associated proteins BAG3 and p62 in testicular cancerGeorg Bartsch, Lukas Jennewein, Patrick N Harter, et al.
BMC Cancer|October 6, 2010
Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinomaNina Wagener, Stephan Macher-Goeppinger, Maria Pritsch, et al.
European Urology|August 31, 2017
Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201)Hendrik Borgmann, Nada Lallous, Deniz Ozistanbullu, et al.
Plos One|December 5, 2025
Complications and oncologic outcome in bladder cancer patients receiving radical cystectomy after intravesical instillation treatmentLisa J Frey, Katarzyna E Banasiewicz, Christian Ruckes, et al.
Pageof 30

Showing results (161-170 of 298) with videos related to

Sort By:
Pageof 30
Translational Oncology|June 10, 2015
Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line TherapeuticsStefan Vallo, Martin Michaelis, Florian Rothweiler, et al.
Urologic Oncology|August 5, 2019
Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancerRene Mager, Olga Savko, Katharina Böhm, et al.
World Journal of Urology|November 1, 2022
Negative multiparametric magnetic resonance imaging for prostate cancer: further outcome and consequencesMaximilian Haack, Vanessa Miksch, Zhe Tian, et al.
World Journal of Urology|June 30, 2025
Impact of the PI-QUAL MRI quality score on histopathological up-staging from MRI fusion biopsy to final prostatectomy specimenMaximilian Haack, Mohamad Turkman, Tobias Jorg, et al.
Cancer Medicine|June 26, 2024
Challenges and perspectives in use of artificial intelligence to support treatment recommendations in clinical oncologyGregor Duwe, Dominique Mercier, Crispin Wiesmann, et al.
Oncology Letters|November 9, 2017
Blocking integrin β1 decreases adhesion in chemoresistant urothelial cancer cell linesStefan Vallo, Jochen Rutz, Miriam Kautsch, et al.
Oncology Reports|December 29, 2015
Autophagy-associated proteins BAG3 and p62 in testicular cancerGeorg Bartsch, Lukas Jennewein, Patrick N Harter, et al.
BMC Cancer|October 6, 2010
Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinomaNina Wagener, Stephan Macher-Goeppinger, Maria Pritsch, et al.
European Urology|August 31, 2017
Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201)Hendrik Borgmann, Nada Lallous, Deniz Ozistanbullu, et al.
Plos One|December 5, 2025
Complications and oncologic outcome in bladder cancer patients receiving radical cystectomy after intravesical instillation treatmentLisa J Frey, Katarzyna E Banasiewicz, Christian Ruckes, et al.
Pageof 30